Modular CAR-T Cell Platform for Adaptive Tumor Targeting

A next-generation CAR-T cell platform enabling adaptive tumor targeting through modular antigen-binding domains, machine learning-based optimization, and real-time monitoring and feedback control, revolutionizing cancer treatment.

The original patent, 'Method for preparing CAR-T cell with TCM as main active component and use thereof,' has limitations in terms of static antigen recognition and lack of adaptability to changing tumor microenvironments. The new inventive concept addresses these limitations by introducing modular antigen-binding domains, machine learning-based optimization, and real-time monitoring and feedback control, enabling CAR-T cells to adapt to dynamic tumor landscapes.

The modular CAR-T cell platform comprises a CAR-T cell with a modular antigen-binding domain, designed to recognize a dynamic range of tumor-associated antigens and adapt to changes in tumor microenvironment. Machine learning-based optimization of T cell receptor sequences enables personalized CAR-T cell generation based on individual patient tumor profiles and genetic data. The platform also incorporates a self-evolving antigen-binding domain, capable of recognizing and adapting to emerging tumor escape mutations. Real-time monitoring and feedback control using AI-powered analytics predict and prevent adverse reactions, optimizing treatment outcomes. Furthermore, in vivo programming of CAR-T cells using CRISPR-Cas9 gene editing enables rapid and targeted modification of CAR-T cell antigen-binding domains in response to changing tumor landscapes.

The new claims introduce a paradigm shift in CAR-T cell therapy by incorporating modular antigen-binding domains, machine learning-based optimization, and real-time monitoring and feedback control, which are not anticipated by the original patent. These innovations enable CAR-T cells to adapt to dynamic tumor landscapes, providing a significant improvement over existing CAR-T cell therapies.

Alternative embodiments of the modular CAR-T cell platform may include the use of different machine learning algorithms, various gene editing techniques, or alternative antigen-binding domain designs. Variations of the platform could also incorporate additional features, such as real-time imaging or personalized neoantigen prediction.

The modular CAR-T cell platform has significant commercial potential in the cancer treatment market, with applications in personalized medicine, immunotherapy, and gene editing. The platform's adaptability and real-time monitoring capabilities position it for widespread adoption in hospitals and research institutions, with potential partnerships with pharmaceutical companies and biotech firms.